The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Georgia Yates
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
 
Kateryna Chepynoga
No Relationships to Disclose
 
Siguroli Teitsson
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Murat Kurt
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Miraj Y. Patel
Employment - Bristol-Myers Squibb/Medarex; CVS Health (I); LEO Pharma; Pfizer (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb/Medarex; CVS Health (I); Sanofi
 
Ronac Mamtani
Honoraria - Flatiron Health
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Genentech/Roche; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Merck